Vanta Bioscience Limited will convene a board meeting on May 30, 2026, to approve the standalone and consolidated audited financial results for the financial year and half year ended March 31, 2026. The meeting is scheduled to take place at 6:00 PM at the company's registered office in Secunderabad. The board will also take note of the audit reports issued by the statutory auditors regarding these financial statements.

Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company intimated the stock exchanges regarding this meeting. The approval of the audited results is a key regulatory requirement for the disclosure of the company's financial performance for FY26.

In continuation of a previous intimation dated March 24, 2026, the company announced that the trading window for all designated persons under its Insider Trading Policy will remain closed. This closure is effective from April 01, 2026, until June 1, 2026, inclusive of both dates, to ensure compliance with insider trading regulations during the period of financial result announcements.

The board's decision on the financial results will provide clarity on the company's fiscal health for the full year and the second half of FY26. The statutory auditors' reports will accompany the results, offering an independent assessment of the financial statements.

Key Meeting Details

Vanta bioscience Limited has submitted its quarterly compliance certificate to BSE Limited, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026.

Regulatory Compliance Submission

The company submitted the certificate on April 10, 2026, in compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The submission was made by Managing Director Dopesh Raja Mulakala to BSE Limited's Corporate Compliance Department.

RTA Confirmation Certificate

Bigshare Services Private Ltd., the company's Registrar and Share Transfer Agent, issued a confirmation certificate dated April 04, 2026. The RTA confirmed that Regulation 74(5) is not applicable to Vanta Bioscience Limited for the quarter ended March 31, 2026.

Non-Applicability Status

The regulation's non-applicability stems from specific operational circumstances during Q4FY26:

• The entire shareholding of the company is maintained in demat form
• No requests for rematerialisation were received from shareholders during the quarter
• No requests for dematerialisation were received from shareholders during the quarter

Corporate Details

Vanta Bioscience Limited operates from its registered office at Umajay Complex, Rasoolpura, Secunderabad. The company maintains its compliance obligations through Bigshare Services Private Ltd., which serves as its official Registrar and Share Transfer Agent.

The submission ensures the company remains compliant with SEBI's regulatory framework governing depositories and participants, maintaining transparency in its shareholding structure and transfer processes.